$SYBX News

Synlogic Receives Nasdaq Delisting Notification, Intends To Switch Trading To OTC

Synlogic Says On Nov 21, Receives Letter From Nasdaq Listing Qualifications Department Stating It Believes Synlogic Is A 'Public Shell', Listing Not Warranted; Co Plans To Request Hearing

We Think Synlogic (NASDAQ:SYBX) Can Afford To Drive Business Growth

Synlogic Announces $150M Mixed Shelf Offering

Synlogic Third Quarter 2024 Earnings: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023)

Synlogic Reports Third Quarter 2024 Financial Results

Synlogic Q3 EPS $(0.01) Up From $(2.57) YoY; Revenue $0 Down From $393K YoY;

Otsuka snaps up Jnana with its phenylketonuria drug for $800m

SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024

Synlogic Reports Second Quarter 2024 Financial Results

Synlogic GAAP EPS of $0.16

Synlogic reports Q2 EPS 16c vs ($3.21) last year

The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits

Chardan Capital Maintains Buy on Synlogic, Lowers Price Target to $5.5

Synlogic Ended FY22 With Cash Balance Of $77.6M With Projected Runway Into 2H 2024

Synlogic Q4 EPS $(0.24) Beats $(0.25) Estimate, Sales $106.00K Miss $220.00K Estimate

The European Medicines Agency Issued A Positive Opinion On Synlogic's Application For Orphan Designation For SYNB1934 For The Treatment Of Phenylketonuria